Biogen Inc
NASDAQ:BIIB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biogen Inc
NASDAQ:BIIB
|
US |
|
T
|
Thales SA
OTC:THLLY
|
FR |
|
V
|
Vow ASA
OSE:VOW
|
NO |
|
Hubbell Inc
NYSE:HUBB
|
US |
|
Toray Industries Inc
TSE:3402
|
JP |
|
Bluejay Diagnostics Inc
NASDAQ:BJDX
|
US |
Wall St Price Targets
BIIB Price Targets Summary
Biogen Inc
According to Wall Street analysts, the average 1-year price target for BIIB is 223.9 USD with a low forecast of 151.5 USD and a high forecast of 315 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BIIB's stock price target?
Price Target
223.9
USD
According to Wall Street analysts, the average 1-year price target for BIIB is 223.9 USD with a low forecast of 151.5 USD and a high forecast of 315 USD.
What is the Revenue forecast for Biogen Inc?
Projected CAGR
2%
Over the last 13 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 3 years is 2%.
What is the Gross Profit forecast for Biogen Inc?
Projected CAGR
3%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 3%. The projected CAGR for the next 3 years is 3%.
What is the Operating Income forecast for Biogen Inc?
Projected CAGR
5%
Over the last 13 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 3 years is 5%.
What is the Pre-Tax Income forecast for Biogen Inc?
Projected CAGR
27%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been -1%. The projected CAGR for the next 3 years is 27%.
What is the Net Income forecast for Biogen Inc?
Projected CAGR
28%
Over the last 13 years, the compound annual growth rate for Net Income has been -1%. The projected CAGR for the next 3 years is 28%.
